Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Hidradenitis Suppurativa,Crohn Disease,Arthritis, Juvenile Rheumatoid,Uveitis,Arthritis, Rheumatoid,Colitis, Ulcerative,Spondylitis, Ankylosing,Skin Diseases, Papulosquamous,Arthritis, Psoriatic, Date of authorisation: 26/07/2018, Revision: 4, Status: Authorised